# Double Blind Placebo Controlled Dose Ranging Study of the Efficacy and Safety of SSR149744c 100 or 300 mg for the Prevention of ventrICular ARrhythmia-triggered Icd interventiOnS

> **NCT00232297** · PHASE2 · COMPLETED · sponsor: **Sanofi** · enrollment: 153 (actual)

## Conditions studied

- Arrhythmia
- Tachycardia, Ventricular
- Ventricular Fibrillation

## Interventions

- **DRUG:** SSR149744C

## Key facts

- **NCT ID:** NCT00232297
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-06
- **Primary completion:** 2007-02
- **Final completion:** 2007-02
- **Target enrollment:** 153 (ACTUAL)
- **Last updated:** 2012-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00232297

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00232297, "Double Blind Placebo Controlled Dose Ranging Study of the Efficacy and Safety of SSR149744c 100 or 300 mg for the Prevention of ventrICular ARrhythmia-triggered Icd interventiOnS". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00232297. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*